Latest

As cell and gene therapy is poised to play a major role in the future of medicine, it’s important to know the basics.

ARM Board Member Miguel Forte highlights CGT investment shifts, sector resilience, and alternative funding strategies during Meeting on the Mesa.

Boosting AI spending, focusing on workforce upskilling, and tackling ethical challenges to drive innovation and product development are top of mind for life science CEOs.

Cellevate’s nanofiber technology enables higher viral vaccine titers in adherent cell cultures, advancing efficiency in large-scale biomanufacturing.

A buffer media station that is currently under construction at Rentschler Biopharma headquarters is expected to contribute to the competitive biotechnology field across Germany and the rest of Europe.

Each step of development and manufacturing is becoming more interconnected, and BioPharm's September/October issue highlights the strategies, tools, and innovations shaping the future of the field.

US President Donald Trump confirmed AstraZeneca as the second of 17 major pharmaceutical companies, after Pfizer, to agree to most-favored-nation pricing protocols.

This second part of a two-part article provides a clear understanding of microbiological load reduction during cleaning processes in the non-sterile pharmaceutical manufacturing.

Scaling biopharma innovation demands advanced manufacturing, global market expansion, and solving patient access barriers.

Jon Ellis, CEO, shares his thoughts on Trenchant BioSystems’ new technology, its reception within the cell and gene therapy sector, and the future nature of industry partnerships.

Comparing our survey results with recent headlines uncovered biopharma’s digital transformation paradox: high potential vs. low adoption.

To increase CAR-T patient access, healthcare professionals must standardize high-quality delivery, shift to outpatient settings, and overcome current logistical barriers, industry leaders said at a session during the Cell and Gene Meeting on the Mesa.

In a session at the Cell and Gene Meeting on the Mesa, Prime Medicine CEO Allan Reine discussed how prime editing offers versatile, safe gene correction, but that delivery to target cells remains a major hurdle.